Author  
Place of duty  
Title   진행성 비소세포페암에 대한 Vinorelbine 과 Carboplatin 의 제 2 상 임상연구 ( A Phase 2 Study with Vinorelbine and Carboplatin in Patients with Advanced Non - small Cell Lung Cancer )
Publicationinfo   2000 Jan; 032(04): 690-699.
Key_word   No - small cell lung cancer, Vinorelbine, Carboplatin, Chemotherapy
Full-Text  
Abstract   Purpose: To evaluate the efficacy and safety of vinorelbine and carboplatin in advanced non- small-cell lung cancer (NSCLC). Materials and Methods: Between August 1998 and July 1999, 25 patients were enrolled. The median age was 68 (range, 46-77) years and male '. female ratio was 23: 2. Two patients had stage IIla, 15 had stage IIIb and 8 had stage IV. Sixteen patients had ECOG performance status of 0 or 1 and 9 had 2 or 3. Sixteen patients had squamous cell carcinoma, 8 had adenocarcinoma and 1 had undifferentiated NSCLC. Treatment consists of intravenous carboplatin 400 mg/m on day 1 and vinorelbine 25 mg/m on days 1 and 8. The treatment was repeated every 28 days. Results: Twenty-three of 25 patients were evaluable. Partial response were observed in 11 patients. The overall response rate was 48% (95% confidence interval: 27-69%) and the median response duration was 19 (range 7+ -44+) weeks. The median survival of 25 patients was 52 (range 3-53) weeks. Toxicities were evaluated by WHO criteria. During a total of 108 cycles, granulocytopenia worse than WHO grade 3 occurred in 2%, thrombocytopenia in 4% and anemia in 10%, respectively. Treatment-related death occurred in 1 patient due to sepsis during cytopenic period. Non-hematologic toxicity was minor and easily controlled. Conclusion: A combination chemotherapy of intravenous vinorelbine and carboplatin has relatively high activity with acceptable toxicities in patients with advanced NSCLC,
저 자   김종률(Jong Lyul Kim),김봉석(Bong Seog Kim),나병주(Byoung Ju Na),소미진(Mi Jin So),이진한(Jin Han Lee),정오영(Oh Young Chung),이귀래(Gwi Lae Lee),노용호(Yong Ho Roh)